ID: ALA4800478

Max Phase: Preclinical

Molecular Formula: C18H18F2N6O3

Molecular Weight: 404.38

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  O[C@@H]1[C@H](O)[C@@H](O)C[C@H]1n1nnc2c(N[C@@H]3C[C@H]3c3ccc(F)c(F)c3)ncnc21

Standard InChI:  InChI=1S/C18H18F2N6O3/c19-9-2-1-7(3-10(9)20)8-4-11(8)23-17-14-18(22-6-21-17)26(25-24-14)12-5-13(27)16(29)15(12)28/h1-3,6,8,11-13,15-16,27-29H,4-5H2,(H,21,22,23)/t8-,11+,12+,13-,15-,16+/m0/s1

Standard InChI Key:  MAPKBGVZYKTCHW-MVWPTHGSSA-N

Associated Targets(Human)

Plasma 7708 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Staphylococcus aureus 210822 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 404.38Molecular Weight (Monoisotopic): 404.1408AlogP: 0.49#Rotatable Bonds: 4
Polar Surface Area: 129.21Molecular Species: NEUTRALHBA: 9HBD: 4
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.92CX Basic pKa: 0.88CX LogP: 0.24CX LogD: 0.24
Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.49Np Likeness Score: -0.84

References

1. Goffin E,Jacques N,Musumeci L,Nchimi A,Oury C,Lancellotti P,Pirotte B.  (2020)  Synthesis of ticagrelor analogues belonging to 1,2,3-triazolo[4,5-d]pyrimidines and study of their antiplatelet and antibacterial activity.,  208  [PMID:32916314] [10.1016/j.ejmech.2020.112767]

Source